CeriBell (NASDAQ:CBLL) Shares Down 3.3% – Should You Sell?

CeriBell (NASDAQ:CBLL)’s stock price traded down 3.3% on Friday . The stock traded as low as $24.66 and last traded at $25.00. 24,940 shares were traded during mid-day trading, a decline of 54% from the average session volume of 54,645 shares. The stock had previously closed at $25.86.

Analyst Ratings Changes

Several analysts have issued reports on the stock. William Blair assumed coverage on shares of CeriBell in a research report on Tuesday, November 5th. They set an “outperform” rating on the stock. Canaccord Genuity Group began coverage on shares of CeriBell in a report on Tuesday, November 5th. They set a “buy” rating and a $30.00 price target for the company. Canaccord Genuity Group boosted their target price on shares of CeriBell from $31.00 to $33.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. TD Cowen lifted their price objective on CeriBell from $31.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Finally, JPMorgan Chase & Co. assumed coverage on shares of CeriBell in a research note on Tuesday, November 5th. They issued an “overweight” rating and a $32.00 price target for the company. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $32.60.

CeriBell Trading Down 4.8 %

The stock’s 50-day moving average price is $27.63.

CeriBell (NASDAQ:CBLL) last announced its earnings results on Tuesday, November 12th. The company reported ($1.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($1.03). The company had revenue of $17.20 million for the quarter, compared to the consensus estimate of $17.06 million. On average, analysts anticipate that CeriBell will post -2.46 EPS for the current year.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.